Folfox protocol: all 84 studies that test it
Page 1 of 1. Open to participants first (29), then studies with results posted, then the rest; newest registration first within each.
- TAIC FOLFOX for Locally Advanced G/GEJARecruitingNCT07655024Phase 2
- Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal AdenocarcinomaRecruitingNCT07603375Phase 2
- Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal CancerRecruitingNCT07562711Phase 2
- Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular CarcinomaNot yet recruitingNCT07522411Phase 1/2
- FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic CholangiocarcinomaNot yet recruitingNCT07353827Phase 2
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingNCT07318389Early Phase 1
- The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal CancerRecruitingNCT07204574Phase 1/2
- Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver MetastasisRecruitingNCT07193862Early Phase 1
- Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & BevacizumabRecruitingNCT07192185Phase 2
- Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II TrialRecruitingNCT07106034Phase 2
- Organ Preservation in Rectal AdenoCa Using Hypofractionated Pelvic RT(Hypo-OPRA)RecruitingNCT06991465Phase 2
- Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric CancerNot yet recruitingNCT06871527Phase 1/2
- Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon CancerRecruitingNCT06783491Phase 3
- Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver EnzymeRecruitingNCT06475352Phase 2
- Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or MoreRecruitingNCT06293625Phase 3
- Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal CancerRecruitingNCT06279351Phase 2
- Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver MetastasisRecruitingNCT06225843Phase 2
- Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal CancerRecruitingNCT06218810Phase 2
- Intraperitoneal Irinotecan With Concomitant FOLFOX and BevacizumabRecruitingNCT06003998Phase 2
- Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)RecruitingNCT05733689Phase 1
- A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic AgentsRecruitingNCT05718492Not applicable
- Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT05702229Phase 2
- Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal CancerRecruitingNCT04991948Phase 1
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)RecruitingNCT04929223Phase 1
- Folfox+Irinotecan+Chemort In Esophageal CancerRecruitingNCT04656041Phase 2
- FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOXRecruitingNCT04167007Phase 3
- Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal CancerNot yet recruitingNCT03975049Phase 3
- alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cellsRecruitingNCT03692429Phase 1
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsRecruitingNCT03526835Phase 1/2
- A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid TumorsCompletedNCT05712356Phase 2Results posted
- Non-Operative Management and Early Response Assessment in Rectal CancerCompletedNCT03904043Not applicableResults posted
- Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal CancerActive, not recruitingNCT03781323Phase 2Results posted
- NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal CancerCompletedNCT03259035Phase 2Results posted
- Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal CancerCompletedNCT01622543Phase 2Results posted
- Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or StomachCompletedNCT01611857Phase 1/2Results posted
- S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction CancerCompletedNCT01498289Phase 2Results posted
- RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal CarcinomaCompletedNCT01047293Phase 1/2Results posted
- Neo-Adjuvant FOLFOX for Rectal CarcinomaTerminatedNCT00832299Phase 2Results posted
- Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon CancerTerminatedNCT00826800Not applicableResults posted
- Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)CompletedNCT00778830Phase 1/2Results posted
- FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric CancerCompletedNCT00673673Phase 2Results posted
- Study Of Sunitinib Plus FOLFOX In Patients With Solid TumorsCompletedNCT00599924Phase 1Results posted
- Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric CardiaCompletedNCT00591123Phase 2Results posted
- Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal CancerCompletedNCT00399035Phase 3Results posted
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction CancerCompletedNCT00381706Phase 2Results posted
- A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal CarcinomatosisTerminatedNCT00352755Phase 2Results posted
- Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS MutationActive, not recruitingNCT06106308Phase 2
- FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal CancerStatus unknownNCT05797883Phase 2
- Adaptive Radiation for Locally Advanced Rectal AdenocarcinomaActive, not recruitingNCT05108428Early Phase 1
- Adjuvant Chemotherapy in High Risk Stage II Colon CancerStatus unknownNCT04303429Phase 3
- HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTCCompletedNCT04217954Phase 2
- A Study of Entinostat and FOLFOX in Subjects With Pancreatic AdenocarcinomaWithdrawnNCT03760614Phase 1
- Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal CancerActive, not recruitingNCT03635021Phase 3
- FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS MutationCompletedNCT03584711Phase 2
- Organ Preservation in Early Rectal Cancer PatientsActive, not recruitingNCT03548961Phase 2
- FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal AdenocarcinomaTerminatedNCT03528876Phase 2
- Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan CriteriaStatus unknownNCT03469479Phase 3
- Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal CancerStatus unknownNCT03377842Phase 2
- NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal CancerStatus unknownNCT03280407Phase 2
- Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRCCompletedNCT03202758Phase 1/2
- Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular CarcinomaCompletedNCT03164382Phase 3
- HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/BCompletedNCT03048123Phase 2
- A Study of OMP-305B83 in Subjects With Metastatic Colorectal CancerTerminatedNCT03035253Phase 1
- Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver MetastasisCompletedNCT03031444Phase 2/3
- Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular CarcinomaCompletedNCT02981498Phase 2
- HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.CompletedNCT02973685Phase 3
- Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel AdenocarcinomaStatus unknownNCT02502370Phase 3
- NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric AdenocarcinomaStatus unknownNCT02486601Phase 2
- Treatment Strategies in Colorectal Cancer Patients with Initially Unresectable Liver-only MetastasesCompletedNCT02162563Phase 3
- Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus FluoropyrimidinesWithdrawnNCT01786538Phase 3
- Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal CancerCompletedNCT01288339Phase 2
- Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric CancerCompletedNCT01283204Phase 2
- A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal CancerCompletedNCT01274962Phase 2
- A Trial of Neoadjuvant FOLFOX6 With Short Course Radiotherapy in Patients With Unresectable Rectal Cancer and Liver MetastasisCompletedNCT01269229Phase 2
- Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.TerminatedNCT01248299Phase 2
- Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon CancerCompletedNCT00994864Not applicable
- Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon CancerActive, not recruitingNCT00958737Phase 3
- A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal CancerCompletedNCT00873756Phase 1
- Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver MetastasesCompletedNCT00866944Phase 2
- A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)CompletedNCT00851136Phase 1
- FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon CancerCompletedNCT00646607Phase 3
- Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOXCompletedNCT00479583Phase 1
- Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)CompletedNCT00153998Phase 2
- Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal CancerCompletedNCT00116506Phase 2